Thursday, May 9, 2013
Researchers at Harvard Medical School have teamed up with vaccine maker Mercia Pharma Inc. to design a next-generation Alzheimer's disease vaccine
with an adjuvant that promotes a beneficial anti-inflammatory
response that the team hopes will enhance b-amyloid
clearance without triggering neuroinflammation.1
Antibodies vs. plaques
Lemere's vaccine, termed MER5101,
consists of the first 15 amino acids of Ab attached by a flexible
covalent linker to diphtheria
toxoid, a carrier protein. The team collaborated
with Mercia to formulate the vaccine in the company's MAS-1
adjuvant, an oil-and-water nanoparticle emulsion.
Although prior vaccine candidates have not
shown the anti-
inflammatory Th2 cell profile seen with MER5101, it remains to be seen whether
the new vaccine's anti-inflammatory effects will improve efficacy in the
Osherovich, L. SciBX 6(18); doi:10.1038/scibx.2013.432
Published online May 9, 2013
1. Liu, B. et al. J.
Neurosci.; published online April 17, 2013;
Contact: Cynthia A. Lemere, Brigham and Women's Hospital and Harvard
Medical School, Boston, Mass.
AND INSTITUTIONS MENTIONED
Baxter International Inc. (NYSE:BAX), Deerfield, Ill.
Brigham and Women's Hospital, Boston, Mass.
Elan Corp. plc (NYSE:ELN), Dublin, Ireland
Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind.
Harvard Medical School, Boston, Mass.
Intellect Neurosciences Inc. (OTCBB:ILNS), New York, N.Y.
Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
Mercia Pharma Inc., New York, N.Y.
Pfizer Inc. (NYSE:PFE), New York, N.Y.
Symphogen A/S, Copenhagen, Denmark